PharmaBlock Sciences(Nanjing),Inc.

  • Micropacked bed reactor at the PharmaBlock Zhejiang manufacturing site
  • Continuous Flow Manufacturing Facility at PharmaBlock Zhejiang
  • PharmaBlock Received 2023 ACS Green Chemistry Award
About PharmaBlock Sciences(Nanjing),Inc.

PharmaBlock  (SZSE:300725) is a CDMO recognized as a pioneer in innovative green technology & a reliable partner of chemistry services throughout pharmaceutical R&D and commercial production. Its businesses start from the legacy of rationally designed building blocks supplied from discovery through development & commercial. Within the last few years, enabled by low-carbon technology such as flow chemistry & biocatalysis, PharmaBlock has gained a reputation as a quality manufacturer of RSM, intermediate, API & DP with a lower cost & greener footprint.

Certifications
  • CN
  • 2016
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Primary activities
API Producer
Chemical Development
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Contact info
  • 10Xuefu Road, Nanjing Hi-Tech Zone, 210032, Nanjing , China

Products from PharmaBlock Sciences(Nanjing),Inc. (18)

PharmaBlock Sciences(Nanjing),Inc. Resources (9)

  • News PharmaBlock Receives 2023 ACS CMO Excellence in Green Chemistry Award

    PharmaBlock has been selected as the winner of the 2023 CMO Excellence in Green Chemistry Award by the American Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable (GCI PR). This award honors and confirms PharmaBlock’s commitment to green chemistry and its achievement in developing innovative solutions for sustainable development in the pharmaceutical industry.
  • Video Innovation at PharmaBlock

    Innovation at PharmaBlock
  • Video Manufacturing Site Virtual Tour

    360° Virtual Tour of Pharmablock Zhejiang GMP Manufacturing Site is ready to go! The virtual tour will provide you an immersive interactive view of the workshops, analytical labs, and the new Chemistry & Engineering Technology Center. Check the demo video below to have a quick look. Contact our BD representatives or the marketing team ([email protected]) for a full interactive version.
  • Brochure PharmaBlock CDMO Capabilities and Chemistry & Engineering Technologies

    Led by an experienced management and core technical team, PharmaBlock is providing development and manufacturing solutions of intermediates, drug substance for development and commercial stages. Taking full advantage of building blocks availabilities, along with its know-hows in chemistry, process development, analytical development, manufacturing, and engineering technologies, the team has distinguished itself for capabilities to tackle challenging chemistry, secure reliable supply, control cost with full compliance of quality and EHS etc.

  • Brochure Chemistry & Engineering Technologies

    PharmaBlock has invested in a number of innovative technologies to enable greener, safer, and more efficient process for manufacturing. We have a dedicated chemistry and engineering technology team working closely with experts in process development and manufacturing to implement optimal process solutions from pilot to commercial scale.

    Capabilities include: flow chemistry, micropacked bed hydrogenation, biocatalysis, heterogeneous catalysis, solid state chemistry, crystallization, engineering technologies etc. 
  • Whitepaper 【Whitepaper】Flow chemistry - An optimized solution for diazotization reaction

    As an emerging technology, continuous flow chemistry is being applied in more and more reactions. On the basis of ensuring safety, the flow chemistry process can facilitate scale-up production, improve quality, and enhance time and cost-efficiency of the diazotization reaction.  PharmaBlock is looking forward to expanding the application range of micro reactors in different reactions. With the increasing demand from customers, reactors of different sizes and types need to be designed and developed to accelerate pharmaceutical manufacturing. Another key point to its future will be the collaboration between AI or automated manufacturing and micro reactor technology to achieve multi-step continuous manufacturing.
  • Whitepaper Application of Continuous Flow Hydrogenation with Micro-packed Bed Reactors on Manufacturing Scale

    With the advancements in continuous flow technology and the ever-increasing demand for green processes, continuous flow chemistry has become more and more widely adopted in the pharmaceutical industry. The usage of micro-packed bed reactors is a viable option for application of continuous flow technology in hydrogenation. However, most of the applications are still at lab-scale. PharmaBlock will continue exploring more types of reduction transformations at manufacturing scale, and enhance the automated control systems.
  • Video Innovation for Sustainability: A Dive Into ACS Green Chemistry Award-Winning Continuous Flow Manufacturing Case Studies

    To improve pharmaceutical supply chain sustainability, it is crucial to place green chemistry and low-carbon technologies, including but not limited to continuous flow chemistry, and biocatalysis, at the forefront of the industry’s sustainability efforts. PharmaBlock's award-winning projects, recognized by the 2023 and 2024 ACS CMO Excellence in Green Chemistry Award, exemplify these sustainable advancements with such innovative technologies. Key discussion points include: 1. Maximizing Sustainability Returns: Enhancing the environmental performance of raw materials and RSMs is crucial for achieving the highest sustainability returns. These intermediates often have a substantial environmental footprint, as their production processes may not be as optimized as those of upstream steps, and they are produced at larger scales compared to downstream processes. 2. Overcoming Flow Technology Challenges: The application of flow technology, especially in hydrogenation and other heterogeneous reactions, presents significant challenges. These include the need for substantial investment in specialized equipment, the development of immobilized catalyst technology, and the integration of process analytical technology. 3. The environmental implications of these